The teleradiology provider Medica Group has announced that it has added Axon Diagnostics to the company.
The business said in a release that the new agreement "reflects a shared vision to accelerate innovation and expand access to high-quality remote diagnostic reporting across the NHS and independent healthcare sector."
Medica will also welcome Axon's sister company, MITIS Health, which brings its Clinical Desktop technology to support high-fidelity remote reporting valued by many NHS Trusts and Axon clients.
Medica’s extensive pool of specialist clinicians, supported by its proven clinical governance and infrastructure, will be strengthened by Axon’s technology platform and workflow tools, together with the Clinical Desktop technology from MITIS.
Axon’s technologies are widely recognised for their agility, user-centric design and access to Clinical Desktop technology that enables high-performance remote desktop access, allowing clinicians to work seamlessly and securely from any appropriate location.
Bringing these complementary strengths together will provide increased capacity, enabling the combined company to deliver an enhanced experience for clients and their patients across the country, at greater speed.
It also means the company is well-positioned to accelerate innovation in areas such as AI-enabled reporting, workflow optimisation and expanded diagnostic services.
Together, the organisations will offer the largest clinical reporting network in the UK, covering major diagnostic subspecialties and providing proven capacity to support routine and urgent cases, including periods of surge demand.
The company will serve more than 2.5 million patients across 55% of all NHS Trusts.
Both organisations have stated that they will remain committed to acting as trusted strategic partners to healthcare providers, offering transparency, consistency and measurable improvements in patient outcomes.
As such, healthcare providers will continue to work with the same trusted teams, ensuring consistency of service while benefiting with time from the expanded capabilities of the combined organisation.
Axon’s advanced reporting technology will be incorporated into Medica’s service offering through a phased integration programme, while clinicians from both organisations will have access to a broader case mix and enhanced tools as systems gradually integrate.
The combined scale and streamlined workflows will also support greater efficiency and cost-effectiveness for clients, aligning with the NHS's long-term priorities.
Andrew Cannon, CEO of Medica Group, said: "This merger marks a significant milestone for Medica and we are proud to welcome Axon into the Medica Group."
"The Axon team has built an exceptional business in a remarkably short time, earning the trust of clients through first-rate service, agility and a deep commitment to quality."
"Bringing Axon into Medica strengthens our position as the UK’s leading diagnostics provider. Clients will continue to receive the excellent service they rely on, now supported by greater capacity and advanced reporting technology."
"We look forward to building a compelling future together, driving further innovation and delivering outstanding patient care at the core of our mission."
Rahul Mehta, CEO of Axon Diagnostics, added: "Axon was founded to push the boundaries of diagnostic innovation and joining Medica enables us to amplify that mission."
"This merger combines our technology and agile approach with Medica’s scale and clinical excellence, meaning more patients will benefit from faster and smarter reporting."
"We’re excited to enter this next chapter together, bringing our teams and clients with us into the Medica Group as we continue building trusted, high-quality diagnostic services."
Medica and Axon are currently implementing a phased integration plan to bring together systems, teams and best practices in a structured and transparent way.